Breast (Feb 2023)
Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)
- Clara Sebbag,
- Christine Rousset-Jablonski,
- Florence Coussy,
- Isabelle Ray-Coquard,
- Clémentine Garin,
- Clémence Evrevin,
- Marion Cessot,
- Julie Labrosse,
- Lucie Laot,
- Lauren Darrigues,
- Angélique Bobrie,
- Claire Sénéchal-Davin,
- Marc Espié,
- Sylvie Giacchetti,
- Geneviève Plu-Bureau,
- Lorraine Maitrot-Mantelet,
- Anne Gompel,
- Pietro Santulli,
- Bernard Asselain,
- Judicaël Hotton,
- Charles Coutant,
- Julien Guerin,
- Christine Decanter,
- Audrey Mailliez,
- Etienne Brain,
- Elise Dumas,
- Laura Sablone,
- Research Network Seintinelles,
- Fabien Reyal,
- Anne-Sophie Hamy
Affiliations
- Clara Sebbag
- Department of Medical Oncology, Institut Curie, Paris, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France; Université Paris Cité, Paris, France
- Christine Rousset-Jablonski
- INSERM U1290 RESearch on HealthcAre PErformance (RESHAPE), University Claude Bernard Lyon 1, Lyon, France; Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
- Florence Coussy
- Department of Medical Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France
- Isabelle Ray-Coquard
- INSERM U1290 RESearch on HealthcAre PErformance (RESHAPE), University Claude Bernard Lyon 1, Lyon, France; Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
- Clémentine Garin
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France
- Clémence Evrevin
- Department of Medical Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France
- Marion Cessot
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
- Julie Labrosse
- Department of Surgical Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France
- Lucie Laot
- Department of Surgical Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France
- Lauren Darrigues
- Department of Surgical Oncology, Institut Curie, Paris, France; Université Paris Cité, Paris, France
- Angélique Bobrie
- Department of Medical Oncology, Institut du cancer de Montpellier, Montpellier, France
- Claire Sénéchal-Davin
- Department of Oncogenetics, Institut Bergonié, Bordeaux, France
- Marc Espié
- Sénolopole, Hôpital Saint Louis, AP-HP, Paris, France; University Paris, Paris France
- Sylvie Giacchetti
- Sénolopole, Hôpital Saint Louis, AP-HP, Paris, France; University Paris, Paris France
- Geneviève Plu-Bureau
- Department of Gynecology, Hôpital Cochin, Paris, France; University Paris, Paris France
- Lorraine Maitrot-Mantelet
- Department of Gynecology, Hôpital Cochin, Paris, France; University Paris, Paris France
- Anne Gompel
- Department of Gynecology, Hôpital Cochin, Paris, France; University Paris, Paris France
- Pietro Santulli
- Department of Gynecology, Hôpital Cochin, Paris, France; University Paris, Paris France
- Bernard Asselain
- Department of Biostatistics, Unicancer, Paris, France
- Judicaël Hotton
- Department of Surgical Oncology, Institut Godinot, Reims, France
- Charles Coutant
- Department of Surgical Oncology, Centre Georges-François Leclerc - Unicancer, Dijon, France; Clinical Research Department, Centre Georges-François Leclerc - Unicancer, Dijon, France
- Julien Guerin
- Data Factory, Data Office, Institut Curie, 25 rue d’Ulm, 75005 Paris, France
- Christine Decanter
- ART department, Centre Hospitalier Regional Lille, Lille, France
- Audrey Mailliez
- Department of Medical Oncology, Centre Oscar Lambert, Lille, France
- Etienne Brain
- Department of Medical Oncology, Institut Curie, Saint-Cloud, France
- Elise Dumas
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France
- Laura Sablone
- Seintinelles Research Network, 40 Rue Rémy Dumoncel, 75014, Paris, France
- Research Network Seintinelles
- Seintinelles Research Network, 40 Rue Rémy Dumoncel, 75014, Paris, France
- Fabien Reyal
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France; Department of Surgical Oncology, Institut Curie, Paris, France; Seintinelles Research Network, 40 Rue Rémy Dumoncel, 75014, Paris, France; Université Paris Cité, Paris, France
- Anne-Sophie Hamy
- Department of Medical Oncology, Institut Curie, Paris, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France; Department of Surgical Oncology, Institut Curie, Paris, France; Seintinelles Research Network, 40 Rue Rémy Dumoncel, 75014, Paris, France; Université Paris Cité, Paris, France; Corresponding author. Department of Medical Oncology, Institut Curie, Paris, France.
- Journal volume & issue
-
Vol. 67
pp. 62 – 70
Abstract
Objective: To compare the prevalence of contraception in breast cancer (BC) patients at risk of unintentional pregnancy (i.e. not currently pregnant or trying to get pregnant) and matched controls. Study design: The FEERIC study (Fertility, Pregnancy, Contraception after BC in France) is a prospective, multicenter case-control study, including localized BC patients aged 18–43 years, matched for age and parity to cancer-free volunteer controls in a 1:2 ratio. Data were collected through online questionnaires completed on the Seintinelles research platform. Results: In a population of 1278 women at risk of unintentional pregnancy, the prevalence of contraception at study inclusion did not differ significantly between cases (340/431, 78.9%) and controls (666/847, 78.6%, p = 0.97). Contrarily, the contraceptive methods used were significantly different, with a higher proportion of copper IUD use in BC survivors (59.5% versus 25.0% in controls p < 0.001). For patients at risk of unintentional pregnancy, receiving information about chemotherapy-induced ovary damage at BC diagnosis (OR = 2.47 95%CI [ 1.39–4.37] and anti-HER2 treatment (OR = 2.46, 95% CI [ 1.14–6.16]) were significantly associated with the use of a contraception in multivariate analysis. Conclusion: In this large French study, BC survivors had a prevalence of contraception use similar to that for matched controls, though almost one in five women at risk of unintentional pregnancy did not use contraception. Dedicated consultations at cancer care centers could further improve access to information and contraception counseling.
